{"disease":{"id":"panic-disorder-pd","name":"panic disorder pd"},"drugs":{"marketed":[{"drug_id":"paroxetine","indication_name":"Panic Disorder (PD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Paroxetine","generic_name":"paroxetine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Serotonin (5-HT) reuptake transporter","drug_class":"Selective Serotonin Reuptake Inhibitor (SSRI)","quality_score":73,"revenue":null,"mechanism":"Inhibits neuronal reuptake of serotonin in the central nervous system, presumed mechanism for treating psychiatric disorders."}],"pipeline":[],"offLabel":[],"totalMarketed":1,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[{"drug_id":"paroxetine","guideline_body":"FDA label","recommendation":"Paroxetine is indicated for the treatment of panic disorder in adults.","line_of_therapy":"1L","evidence_grade":"A","guideline_year":null}],"source":"Drug Landscape verified database"}